Neuberger Berman Canada’s Impax Laboratories, Inc. IPXL Stock Holding History

Neuberger Berman Canada’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-19,300	Closed	-$485K	–	300
2013 Q4	$485K	Sell	19,300 -28,700	-60%	-$640K	0.11%	183
2013 Q3	$983K	Buy	+48,000	New	+$991K	0.29%	109

Other funds holding IPXL

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Neuberger Berman Canada's IPXL Position: Q1 2014 in Review

Neuberger Berman Canada sold out of Impax Laboratories, Inc. (IPXL) in Q1 2014, closing a stake of 19,300 shares — an estimated $485K sold.

Neuberger Berman Canada first reported a position in IPXL in Q3 2013 and held it in 2 quarters. The position peaked at $983K in Q3 2013. 181 funds tracked by Wall St. Rank hold IPXL as of Q1 2014.

Neuberger Berman Canada reported no remaining Impax Laboratories, Inc. position as of Q1 2014 after selling out during the quarter.
Neuberger Berman Canada sold 19,300 Impax Laboratories, Inc. shares in Q1 2014, an estimated $485K.
Neuberger Berman Canada first reported a position in Impax Laboratories, Inc. in Q3 2013 and held it in 2 quarters.
Neuberger Berman Canada's Impax Laboratories, Inc. position peaked at $983K in Q3 2013.
181 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2014.

Based on Neuberger Berman Canada's 13F filing for Q1 2014, filed 28 Apr 2014.